It is now a given that 250 MACE will be achieved in the next few weeks and that topline results will come out in mid-year as stated.  That in and of itself no longer seems truly noteworthy in terms of it being a ‘surprise’.  Further, the market has likely already factored that information into the current share price (but ok, who knows?).  So, it all comes down to the topline result and the devil in the detail further down the road.

To a simpleton like me, topline data will either report achievement of the primary endpoint for DM or it won’t.  It will presumably also detail some information on the secondary indications.

My question is this, can the topline result for the primary endpoint also possibly described as being (and I hate this word), inconclusive?  If so, who knows what can happen, if anything. Apabetalone then possibly languish in the clinical trial netherworld and then gradually fade from view, or be of some use but not in the way we all hope.   

Statistically, it would seem that the primary endpoint will be achieved or it won’t, there is no ‘in between’.  Right?

Thanks,